Analysts Offer Insights on Healthcare Companies: Labcorp Holdings (LH), Recursion Pharmaceuticals (RXRX) and Johnson & Johnson (JNJ)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Labcorp Holdings (LH), Recursion Pharmaceuticals (RXRX) and Johnson & Johnson (JNJ).
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Labcorp Holdings (LH)
In a report released today, Luke Sergott from Barclays maintained a Hold rating on Labcorp Holdings, with a price target of $290.00. The company’s shares closed last Monday at $264.18.
According to TipRanks.com, Sergott has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Labcorp Holdings with a $308.63 average price target, a 19.1% upside from current levels. In a report issued on April 10, TipRanks – xAI also reiterated a Hold rating on the stock with a $290.00 price target.
See the top stocks recommended by analysts >>
Recursion Pharmaceuticals (RXRX)
Needham analyst Gil Blum maintained a Buy rating on Recursion Pharmaceuticals today and set a price target of $8.00. The company’s shares closed last Monday at $3.42.
According to TipRanks.com, Blum is a 4-star analyst with an average return of
Currently, the analyst consensus on Recursion Pharmaceuticals is a Moderate Buy with an average price target of $7.00.
Johnson & Johnson (JNJ)
In a report released today, Lee Hambright from Bernstein maintained a Hold rating on Johnson & Johnson. The company’s shares closed last Monday at $237.96.
According to TipRanks.com, Hambright is a 1-star analyst with an average return of
Johnson & Johnson has an analyst consensus of Moderate Buy, with a price target consensus of $254.93, representing a 7.2% upside. In a report issued on April 2, J.P. Morgan also maintained a Hold rating on the stock with a $250.00 price target.
Read More on LH:
